(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 58.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Zevra Therapeutics's revenue in 2025 is $62,020,000.On average, 10 Wall Street analysts forecast ZVRA's revenue for 2025 to be $5,784,721,128, with the lowest ZVRA revenue forecast at $5,281,189,361, and the highest ZVRA revenue forecast at $6,165,317,045.  On average, 10 Wall Street analysts forecast ZVRA's revenue for 2026 to be $8,923,234,065, with the lowest ZVRA revenue forecast at $7,459,792,243, and the highest ZVRA revenue forecast at $10,792,532,596.  
In 2027, ZVRA is forecast to generate $14,388,546,525 in revenue, with the lowest revenue forecast at $11,629,506,802 and the highest revenue forecast at $18,566,681,348.